September 29, 2026
Lilly's Zepbound (tirzepatide 10 mg and 15 mg) was associated with more weight loss than Wegovy HD (semaglutide injection 7.2 mg) in a new indirect treatment comparison
Investors
Clinical Development Pipeline
Learn More
Quarterly Results
View Results
2025 Year in Review
View This Report
Key Ratios
Key Financial Ratios
Sustainability Report
Learn More
Latest Sustainability Developments
View Stories

Investor Email Alerts
Sign up to receive email alerts for various types of investor content.